|
Clinical variable
|
Pre-HSCTa
|
BOS diagnosis
|
3 months treatment
|
Change of lung function between 3 months treatment and BOS diagnosis
|
P-value (BOS diagnosis vs 3 months treatment)
|
|---|
|
FVC (L)
|
3.70 ± 0.86
|
2.95 ± 0.81
|
3.18 ± 0.81
|
0.23 ± 0.43
|
< .001
|
|
FVC (% predicted)
|
94.14 ± 12.71
|
73.02 ± 13.23
|
78.41 ± 13.87
|
5.39 ± 10.11
|
< .001
|
|
FEV1 (L)
|
2.94 ± 0.69
|
1.85 ± 0.57
|
2.07 ± 0.68
|
0.22 ± 0.43
|
< .001
|
|
FEV1 (% predicted)
|
96.00 ± 13.68
|
56.68 ± 15.48
|
63.03 ± 19.31
|
6.36 ± 12.72
|
< .001
|
|
FEV1/FVC (%)
|
79.86 ± 7.14
|
63.80 ± 15.34
|
65.83 ± 16.25
|
2.04 ± 8.09
|
.054
|
|
RV(L)
|
1.37 ± 0.38
|
2.04 ± 0.70
|
1.84 ± 0.68
|
−0.20 ± 0.47
|
.005
|
|
RV (% predicted)
|
79.23 ± 17.64
|
114.24 ± 36.48
|
100.41 ± 34.06
|
−12.90 ± 25.71
|
.005
|
|
TLC (L)
|
5.11 ± 1.06
|
5.03 ± 1.13
|
5.07 ± 1.07
|
0.04 ± 0.46
|
.510
|
|
TLC (% predicted)
|
92.93 ± 10.80
|
89.04 ± 12.31
|
88.82 ± 11.09
|
0.45 ± 7.65
|
.675
|
|
RV/TLC (%)
|
27.02 ± 5.65
|
40.35 ± 9.79
|
36.12 ± 10.28
|
−4.35 ± 7.34
|
< .001
|
|
RV/TLC (% predicted)
|
83.50 ± 15.77
|
125.71 ± 33.70
|
111.22 ± 33.98
|
−14.06 ± 24.22
|
< .001
|
|
DLCO (% predicted)
|
62.05 ± 15.51
|
62.39 ± 17.46
|
66.32 ± 18.38
|
4.41 ± 13.80
|
.027
|
-
aFour missing values in Pre-HSCT (N = 57). Data represent the mean ± SD. P-values shown in bold are significant at the 0.05 level. HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, FVC forced vital capacity, FEV1 forced expiratory volume in 1s, RV residual volume, TLC total lung capacity, DLCO carbon monoxide diffusion in the lung
